Download PDF
CC BY 4.0 · Glob Med Genet 2020; 07(01): 003-007
DOI: 10.1055/s-0040-1713610
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Cancer Treatment: An Epigenetic View

Cansu Aydin
2   Department of Molecular Biology and Genetics, Faculty of Medicine, Trakya University, Merkez/Edirne, Turkey
,
Rasime Kalkan
1   Department of Medical Genetics, Faculty of Medicine, Near East University, Nicosia, Turkish Republic of Northern Cyprus
› Author Affiliations
Further Information

Publication History

Publication Date:
15 July 2020 (online)

Also available at
   Permissions and Reprints

Abstract

Cancer can be identified as an uncontrolled growth and reproduction of cell. Accumulation of genetic aberrations (mutations of oncogenes and tumor-suppressor genes and epigenetic modifications) is one of the characteristics of cancer cell. Increasing number of studies highlighted importance of the epigenetic alterations in cancer treatment and prognosis. Now, cancer epigenetics have a huge importance for developing novel biomarkers and therapeutic target for cancer. In this review, we will provide a summary of the major epigenetic changes involved in cancer and preclinical results of epigenetic therapeutics.

Keywords

cancer - treatment - epigenetics - epidrugs - methylation
 

  • References

  • 1 Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009; 41 (01) 199-213
    CrossrefPubMedGoogle Scholar
  • 2 Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358 (11) 1148-1159
    CrossrefPubMedGoogle Scholar
  • 3 Svedružić ŽM. Dnmt1 structure and function. Prog Mol Biol Transl Sci 2011; 101: 221-254
    PubMedGoogle Scholar
  • 4 Yu J, Xie T, Wang Z. , et al. DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs. Drug Discov Today 2019; 24 (12) 2323-2331
    CrossrefPubMedGoogle Scholar
  • 5 Fukushige S, Horii A. DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers. Tohoku J Exp Med 2013; 229 (03) 173-185
    CrossrefPubMedGoogle Scholar
  • 6 Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012; 22 (01) 50-55
    CrossrefPubMedGoogle Scholar
  • 7 Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harb Perspect Biol 2016; 8 (04) a019521
    CrossrefPubMedGoogle Scholar
  • 8 Kim JE. Bookmarking by histone methylation ensures chromosomal integrity during mitosis. Arch Pharm Res 2019; 42 (06) 466-480
    CrossrefPubMedGoogle Scholar
  • 9 Erdel F. How communication between nucleosomes enables spreading and epigenetic memory of histone modifications. BioEssays 2017 39. (12)
    PubMedGoogle Scholar
  • 10 Kutateladze TG, Gozani O, Bienz M, Ostankovitch M. Histone modifications for chromatin dynamics and cellular plasticity. J Mol Biol 2017; 429 (13) 1921-1923
    CrossrefPubMedGoogle Scholar
  • 11 Esteller M. Epigenetic drugs: more than meets the eye. Epigenetics 2017; 12 (05) 307
    CrossrefPubMedGoogle Scholar
  • 12 Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8 (04) 286-298
    CrossrefPubMedGoogle Scholar
  • 13 Xin B, Rohs R. Relationship between histone modifications and transcription factor binding is protein family specific. Genome Res 2018
    PubMedGoogle Scholar
  • 14 Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010; 70: 27-56
    CrossrefPubMedGoogle Scholar
  • 15 Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009; 1 (02) 239-259
    CrossrefPubMedGoogle Scholar
  • 16 Tse JWT, Jenkins LJ, Chionh F, Mariadason JM. Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?. Trends Cancer 2017; 3 (10) 698-712
    PubMedGoogle Scholar
  • 17 Deng P, Chang XJ, Gao ZM. , et al. Downregulation and DNA methylation of ECRG4 in gastric cancer. OncoTargets Ther 2018; 11: 4019-4028
    Google Scholar
  • 18 Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett 2014; 342 (02) 200-212
    CrossrefPubMedGoogle Scholar
  • 19 Anwar SL, Lehmann U. DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol 2014; 20 (24) 7894-7913
    CrossrefPubMedGoogle Scholar
  • 20 Faryna M, Konermann C, Aulmann S. , et al. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J 2012; 26 (12) 4937-4950
    CrossrefPubMedGoogle Scholar
  • 21 Lund RJ, Huhtinen K, Salmi J. , et al. DNA methylation and transcriptome changes associated with cisplatin resistance in ovarian cancer. Sci Rep 2017; 7 (01) 1469
    CrossrefPubMedGoogle Scholar
  • 22 Putiri EL, Robertson KD. Epigenetic mechanisms and genome stability. Clin Epigenetics 2011; 2 (02) 299-314
    CrossrefPubMedGoogle Scholar
  • 23 Toyota M, Suzuki H, Yamashita T. , et al. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci 2009; 100 (05) 787-791
    CrossrefPubMedGoogle Scholar
  • 24 Soshnev AA, Josefowicz SZ, Allis CD. Greater than the sum of parts: complexity of the dynamic epigenome. Mol Cell 2016; 62 (05) 681-694
    CrossrefPubMedGoogle Scholar
  • 25 Irizarry RA, Ladd-Acosta C, Wen B. , et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41 (02) 178-186
    CrossrefPubMedGoogle Scholar
  • 26 Peedicayil J. The role of DNA methylation in the pathogenesis and treatment of cancer. Curr Clin Pharmacol 2012; 7 (04) 333-340
    CrossrefPubMedGoogle Scholar
  • 27 Castillo-Aguilera O, Depreux P, Halby L, Arimondo PB, Goossens L. DNA methylation targeting: the DNMT/HMT crosstalk challenge. Biomolecules 2017; 7 (01) E3
    CrossrefPubMedGoogle Scholar
  • 28 Miller CM, Harris EN. Antisense oligonucleotides: treatment strategies and cellular internalization. RNA Dis 2016; 3 (04) e1393
    PubMedGoogle Scholar
  • 29 Xu P, Hu G, Luo C, Liang Z. DNA methyltransferase inhibitors: an updated patent review (2012–2015). Expert Opin Ther Pat 2016; 26 (09) 1017-1030
    CrossrefPubMedGoogle Scholar
  • 30 Heuser M, Yun H, Thol F. Epigenetics in myelodysplastic syndromes. Semin Cancer Biol 2018; 51: 170-179
    CrossrefPubMedGoogle Scholar
  • 31 Jiang LC, Luo JM. Role and mechanism of decitabine combined with tyrosine kinase inhibitors in advanced chronic myeloid leukemia cells. Oncol Lett 2017; 14 (02) 1295-1302
    CrossrefPubMedGoogle Scholar
  • 32 Orta ML, Pastor N, Burgos-Morón E. , et al. Zebularine induces replication-dependent double-strand breaks which are preferentially repaired by homologous recombination. DNA Repair (Amst) 2017; 57: 116-124
    CrossrefPubMedGoogle Scholar
  • 33 Schrump DS, Fischette MR, Nguyen DM. , et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12 (19) 5777-5785
    CrossrefPubMedGoogle Scholar
  • 34 Gros C, Fahy J, Halby L. , et al. DNA methylation inhibitors in cancer: recent and future approaches. Biochimie 2012; 94 (11) 2280-2296
    CrossrefPubMedGoogle Scholar
  • 35 Subramaniam D, Thombre R, Dhar A, Anant S. DNA methyltransferases: a novel target for prevention and therapy. Front Oncol 2014; 4: 80
    PubMedGoogle Scholar
  • 36 Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006; 66 (05) 2500-2505
    CrossrefPubMedGoogle Scholar
  • 37 Fang MZ, Wang Y, Ai N. , et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63 (22) 7563-7570
    PubMedGoogle Scholar
  • 38 Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 2003; 63 (16) 4984-4989
    PubMedGoogle Scholar
  • 39 Parker BS, Cutts SM, Nudelman A, Rephaeli A, Phillips DR, Sukumar S. Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells. Cancer Biol Ther 2003; 2 (03) 259-263
    CrossrefPubMedGoogle Scholar
  • 40 Zhang C, Zhong JF, Stucky A, Chen X-L, Press MF, Zhang X. Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia. Clin Epigenetics 2015; 7: 117
    CrossrefPubMedGoogle Scholar
  • 41 Morris MJ, Monteggia LM. Unique functional roles for class I and class II histone deacetylases in central nervous system development and function. Int J Dev Neurosci 2013; 31 (06) 370-381
    CrossrefPubMedGoogle Scholar
  • 42 Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015; 20 (03) 3898-3941
    CrossrefPubMedGoogle Scholar
  • 43 Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012; 6 (06) 579-589
    CrossrefPubMedGoogle Scholar
  • 44 Byrd JC, Marcucci G, Parthun MR. , et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105 (03) 959-967
    PubMedGoogle Scholar
  • 45 Pilatrino C, Cilloni D, Messa E. , et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005; 104 (01) 101-109
    CrossrefPubMedGoogle Scholar
  • 46 Gilbert J, Baker SD, Bowling MK. , et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001; 7 (08) 2292-2300
    PubMedGoogle Scholar
  • 47 Ryan QC, Headlee D, Acharya M. , et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005; 23 (17) 3912-3922
    CrossrefPubMedGoogle Scholar
  • 48 Zeller C, Brown R. Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. Ther Adv Med Oncol 2010; 2 (05) 319-329
    CrossrefPubMedGoogle Scholar
  • 49 Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 2009; 100 (05) 758-763
    CrossrefPubMedGoogle Scholar
  • 50 Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21 (01) 103-107
    CrossrefPubMedGoogle Scholar
  • 51 Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001; 61 (19) 7025-7029
    PubMedGoogle Scholar
  • 52 Gore SD, Baylin S, Sugar E. , et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66 (12) 6361-6369
    CrossrefPubMedGoogle Scholar